v3.26.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company operates as one operating segment focused on developing and commercializing innovative therapeutics primarily in the U.S. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the chief executive officer, who is the Company's chief operating decision maker, or CODM, in assessing segment performance and deciding how to allocate resources on a consolidated basis.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using income from operations. Net income is also a measure that is considered in monitoring budget versus actual results. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents information about reported segment revenues, segment profit and significant segment expenses for the three months ended March 31, 2026 and 2025:
 Three Months Ended March 31,
 20262025
Revenues$53,544 $57,336 
Less:
Direct cost of product and other revenue10,033 5,059 
Panion royalty2,257 2,566 
Research and development14,807 9,754 
Selling, general and administrative30,436 25,742 
License707 701 
Income (loss) from operations(4,696)13,514 
Other income (expense)
Interest expense(4,691)(7,770)
Other income3 213 
Change in fair value of warrant liability456 155 
Income (loss) before income taxes(8,928)6,112 
Income tax expense(126)— 
Net income (loss)$(9,054)$6,112